CNBC reporter 是否故意撒谎，导致半个小时big selloff， 30% down。
Quote from CEO at conference "could not ask for better results from a P1 trial". P3 trial to begin in September。1-2 billion doses in the coming year. Started production in 7 countries。
Edward Belongia, an epidemiologist and vaccine researcher at the Marshfield Clinic Research Institute in Wisconsin. “Having said that, it looks very promising — at least as promising if not more so than the other vaccines we’ve looked at.”
SEEKING ALPHA HAD TO ISSUE A CORRECTION!
"Novavax rebounds from vaccine data-stoked selloff on clarified safety profile
Aug. 4, 2020 4:34 PM ET|About: Novavax, Inc. (NVAX)|By: Douglas W. House, SA News Editor
Novavax (NASDAQ:NVAX) announces positive results from the first portion of its Phase 1/2 clinical trial evaluating its COVID-19 vaccine candidate, NVX-CoV2373, with and without the Matrix-M adjuvant, in healthy adults between 18 and 59 years of age.
NVX-CoV2373 was well-tolerated with mild reactogenicity events, mostly injection site pain and tenderness, while systemic events, less frequent, included headache, fatigue and myalgia (muscle pain) after dose 1 (5 µg). Reactogenicity was greater after dose 2 (25 µg) as expected since it was a higher dose. The average duration of events was less than two days.
On the immunogenicity front, the vaccine induced 100% neutralization titers in all participants. All subjects developed anti-spike IgG antibodies after one dose while many also developed wild-type virus neutralizing antibody responses. After the second dose, all participants developed wild-type virus neutralizing antibody responses. The IgG responses were highly correlated with neutralization titers.
选择“Disable on www.wenxuecity.com”
选择“don't run on pages on this domain”
